Treatment sequencing in metastatic castrate-resistant prostate cancer

Treatment sequencing in metastatic castrate-resistant prostate cancer

Six different treatments have demonstrated improved survival in phase III trials targeted to patients with metastatic castration-resistant prostate cancer (mCRPC). Front-line therapeutic options for mCRPC include docetaxel, sipuleucel-T, abiraterone and radium-223. Post-docetaxel options include cab...

Full description

Bibliographic Details
Main Authors: Oliver Sartor, Silke Gillessen
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-06-01
Series:Asian Journal of Andrology
Subjects:
abiraterone; cabazitaxel; castrate-resistant; docetaxel; enzalutamide; radium-223; sipuleucel-T
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=426;epage=431;aulast=Sartor

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=426;epage=431;aulast=Sartor

Similar Items